Xcout Intel
Curevo, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Curevo, Inc. among biotechnology companies — ranked by similarity to what Curevo, Inc. actually does, not by market-cap band.
Subscribe to see Curevo, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Curevo, Inc.
Curevo, Inc. is a biopharmaceutical company headquartered in Bothell, Washington. The company is focused on the research and clinical development of innovative vaccine technologies.
Curevo, Inc. at a glance
Curevo, Inc. is a biotechnology company headquartered in United States. It has raised at least $192M across the 3 funding rounds on record. Its most recent funding round, Series B, raised $110M in March 2025. Xcout tracks 12 named people at Curevo, Inc., including Simeon George (CEO).
Curevo, Inc. leadership
- Simeon GeorgeCEO
- Gregory S. CurhanCFO
- Guy De La RosaCMO
- Andrea WangSr. VP CMC Operations
- David MillerVP, Strategic Communications
- Emma FritzenVP, Operations
6 more named people on record for Curevo, Inc., with roles, board committees and tenure — see the full roster →
Curevo, Inc. funding rounds
At least $192M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $110M | 8 named | |
| SEC Form D filing | $22M | — | |
| Series B | $60M | 9 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Curevo, Inc. news
Top 12 Curevo, Inc. competitors
Ranked by semantic similarity — how close each company is to Curevo, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Icosavax, Inc. is a Seattle, Washington-based clinical-stage biopharmaceutical company specializing in developing novel vaccines utilizing virus-like particle technology.
Similar biotechnology company
MalarVx, Inc. is a clinical-stage biopharmaceutical vaccine company located in Seattle, Washington, founded to develop innovative vaccines addressing global infectious diseases.
Similar biotechnology company
Aptevo Therapeutics Inc. is a public, clinical-stage biotechnology company headquartered in Seattle, Washington, focused on developing novel bispecific and trispecific immunotherapies for immuno-oncology.
Similar biotechnology company
Umoja Biopharma is a biotechnology research company headquartered in Seattle, Washington, focused on developing next-generation immunotherapies.
Life Sciences
Deverra Therapeutics, Inc. is a private biotechnology company founded in 2015 and headquartered in Seattle, Washington, focused on developing drug pipelines and therapeutic solutions.
Biotech
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also advancing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Therapeutics Inc. operates from its headquarters located in Seattle, Washington.
Similar biotechnology company
VitriVax, Inc. is a biotechnology company headquartered in Boulder, Colorado, dedicated to eliminating barriers to global vaccination. The company develops innovative vaccine formulation and stabilization technologies.
Similar biotechnology company
Affinivax, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, that pioneered a novel class of multiplex vaccine technologies.
Biotech
Just-Evotec Biologics is a Seattle-based subsidiary of Evotec SE focused on innovative biologics drug discovery and manufacturing. Operating research and production facilities such as J.POD in Washington State, the company develops technologies for global access to biotherapeutics. It partners with major philanthropic organizations like the Gates Foundation to advance global health.
Similar biotechnology company
SystImmune, Inc. is a clinical-stage bio-pharmaceutical company founded in 2014 and located in Redmond, Washington. The company is focused on the treatment of cancer through developing novel therapeutics and biopharmaceuticals.
Similar biotechnology company
Centivax is a privately held, clinical-stage biotechnology company headquartered in South San Francisco, California. The company focuses on accelerating the transition to a post-pathogen world by developing broad-spectrum vaccines, COVID-19 therapeutics, and antivenom antibodies.
Similar biotechnology company
Receptor Life Sciences, Inc. is a pharmaceutical company based in Seattle, Washington, that applies innovative technologies to develop therapeutic products.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Curevo, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Curevo, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →